FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 417 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer... February 23, 2023 She Faced Breast Cancer At 16 With Little Help From Doctors.... June 21, 2019 EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec April 24, 2026 Cancer Survivors Face High Rates of Housing Insecurity February 5, 2022 Load more HOT NEWS Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context How I Learned to Advocate for Myself During Cancer: “Your Stories”... EMA Recommends Granting a Marketing Authorisation for Tisotumab Vedotin FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a...
